Meinian Onehealth and JingSan Tech Jointly Launch China's First Multi-Dimensional Brain Health Early Screening Product 'BrainRuiJia'

Meinian Onehealth has also ventured into the vast frontier of brain science, opening a new door for the advancement of neuroscience and the prevention and treatment of brain disorders.

Recently, at the First China Brain Health Innovation Summit held in Shanghai, a leading enterprise in preventive medicineMeinian Onehealth Group and JingSan Tech, an AI innovation enterprise, announced a strategic partnership to jointly launch China’s first multi-dimensional intelligent assessment product for brain health risks—“Nao Rui Jia”—marking the commencement of large-scale intelligent early screening services for brain health.This marks the first time that two companies have jointly proposed the concept of early brain health screening at the preventive stage of health checkups, aiming to shift the prevention threshold forward for major neurological disorders such as Alzheimer’s disease and stroke, thereby truly achieving early detection and early treatment of complex brain diseases and actively improving the brain health status of the Chinese population.

On-site of the 1st China Brain Health Innovation Summit and “Nao Rui Jia” Product Launch

Yu Rong (left), Chairman of Meinian Onehealth Healthcare Group, and Shen Yiling (right), Founder and CEO of Jingsan Technology

It is understood that “Nao Rui Jia,” developed by a team of scientists from the University of Cambridge with over a decade of research accumulation, has been trained on hundreds of millions of data points and possesses proprietary technologies such as models for early detection of brain functional decline and assessment of brain health risks. Meinian Onehealth has long been deeply engaged in the field of preventive medicine. It not only commands vast health big data but has also established an extensive professional health examination service network across mainland China, with 613 examination centers providing annual health check-up services to approximately 30 million people, thereby creating an entry point for brain disease screening.

The “Nao Rui Jia” product, jointly launched by Meinian Onehealth and Jingsan Technology, is the result of three years of exploration and refinement of operational models, leveraging the combined strengths of both parties. This collaboration is expected to establish early screening standards for brain health check-ups, including standards for MRI image acquisition and brain health risk assessment.

Leveraging its core technologies and self-built health examination service network, Meinian Onehealth is well-positioned to drive the innovation and iteration of brain health products, facilitate large-scale brain health screening, and lay the foundation for serving tens of millions of customers at risk of brain disorders.

Brain diseases have long been a major public health issue. The World Health Organization’s quantitative assessments have notedAmong the global societal burden caused by various diseases, brain disorders have surpassed cardiovascular diseases and cancer, accounting for 28%.The number of patients with various brain disorders, including neurodevelopmental disorders, mental illnesses, and neurodegenerative diseases, has approached 130 million.

However, due to the high complexity of the human brain and the significant challenges in detecting human brain functional networks and disease-related neural circuits,Currently, there is a widespread lack of effective diagnostic and therapeutic approaches for related diseases.Taking Alzheimer’s disease as an example, since 1998, 100 drugs have been tested worldwide, but only a handful have been approved for use. Moreover, their indicated populations and symptoms are highly restricted, and their real-world effectiveness remains suboptimal.

Early screening, early diagnosis, and early intervention are the primary measures to reduce the incidence of brain diseases.

At the inaugural China Brain Health Innovation Summit, Wang Jianye, Director of the National Center for Geriatric Medicine, President of the Organ Function Quantitative Management Branch of the Chinese Health Management Association, and former President of Beijing Hospital, mentioned“Early screening and diagnosis of brain diseases are crucial. China needs to establish a new paradigm for the precise prevention, diagnosis, and treatment of brain health and related neuropsychiatric disorders across the entire lifecycle. Achieving this requires not only that the public develop a correct understanding of brain health, but also that basic brain science research and its industrial translation undergo in-depth development. Fortunately, technologies such as neuroimaging analysis, tractography, 3D reconstruction of brain regions, quantitative neuroimaging analysis, and early screening and diagnosis of Alzheimer’s disease have all advanced to a certain extent. These advancements hold significant value for enhancing the precision and standardization of diagnosis, assisting in surgical planning and assessment, and improving the efficiency of diagnosis and treatment.”

As Wang Jianye stated, risk assessment is indeed a crucial step in enhancing patients’ awareness of risks and adherence to medical advice, promoting proactive health management, and thereby reducing the incidence of brain disorders. The “Healthy China 2030” Plan proposes implementing prevention-first strategies and strengthening the integrated development of prevention, treatment, rehabilitation, and management for brain health–related conditions such as stroke and dementia. It also aims to promote scientific popularization of brain health and improve public understanding, thereby comprehensively enhancing the brain health quality of the national population.

The launch of the “National Stroke Prevention and Control Million Disability Reduction Project” further underscores the strategic value of preventing and treating brain diseases. Its guiding principles—“shifting the focus upstream and decentralizing resources; enhancing health literacy with education as the priority; fostering interdisciplinary collaboration for standardized prevention and treatment; conducting high-risk screening and implementing targeted interventions”—are, moreover,It outlines the strategic direction of enhancing brain health by preventing and treating brain diseases, raising awareness of high-risk factors for brain health, and increasing the number of screenings among populations at high risk for stroke.

Amidst the accelerating aging of the population, the brain imaging industry has undoubtedly entered a “strategic window period” for development, serving as a potent remedy to reduce the prevalence of stroke and dementia, thereby alleviating the burdens on families, society, and the nation. Although many pioneers in the prevention and treatment of brain diseases have launched their own “arks,” numerous challenges remain to be overcome during the practical implementation phase.

Meinian Onehealth, in collaboration with Jingsan Technology, has launched “Nao Rui Jia,” an innovative product for early screening of brain health. This initiative will usher in a model of large-scale intelligent early screening services for brain health, undoubtedly offering valuable insights for the prevention and control of brain diseases.

It is understood that Meinian Onehealth and Jingsan Technology have jointly launched “Nao Rui Jia,” an intelligent multi-dimensional brain health risk assessment product, primarily targeting early screening for dementia (with a focus on Alzheimer’s disease) and stroke (with a focus on ischemic stroke). This solution comprises two products: “Intelligent Assessment of Cognitive Risk” and “Intelligent Assessment of Stroke Risk,” whileThe core value of this product lies in its ability to predict the risk of brain diseases over the next decade, a capability that cannot be achieved by any single indicator. Meanwhile, this brain health risk model was developed by a team of scientists from the University of Cambridge, validated by domestic neurology experts, and based on more than three generations of community-based studies.

Among them, the intelligent assessment product for cognitive risk features early detection of brain functional decline and ultra-early warning of dementia risk.The screening panel includes a self-assessment scale for brain health, whole-brain volumetric MRI, APOE genotyping, evaluation of over 100 brain regions and cognitive functions, as well as general physical examinations and blood lipid and glucose tests. By integrating multi-dimensional health checkup data with AI-driven quantitative analysis of brain atrophy, the system calculates the risk of cognitive impairment over the next ten years.

The testing items for the intelligent stroke risk assessment product includeBrain Health Self-Assessment Scale, Carotid Plaque MRI Examination, Plaque Stability Assessment, APOE Gene Testing, Folate Metabolism Capacity Evaluation, General Physical Examination, Blood Glucose and Lipid Testing, etc. By integrating health indicators across more than 30 dimensions and combining vascular morphology with quantitative plaque analysis techniques, it calculates the ten-year risk of stroke.

At the summit, Professor Teng Zhongzhao, Senior Researcher at the University of Cambridge and Chief Scientist at Jingsan Technology, provided a detailed introduction to the “Nao Rui Jia” technology and stated“BrainRuiJia” establishes a personalized vertical database for brain health based on medical examination data, including neuroimaging, genetic heritage, molecular metabolism, behavioral characteristics, and lifestyle habits. By applying artificial intelligence algorithms and big data risk modeling to multi-scale, multi-modal, and multi-dimensional diagnostic information, it assesses the risk of cognitive impairment and dementia. Furthermore, “BrainRuiJia” can provide early warning signals up to ten years in advance, identify high-risk factors, and formulate personalized health management plans for examinees, thereby enabling targeted intervention and management for brain health.

Professor Teng Zhongzhao, Senior Research Fellow at the University of Cambridge and Chief Scientist at Jingsan Technology, Introduces the “Nao Rui Jia” Product

In the future, Meinian Onehealth will collaborate with Jingsan Technology to continuously iterate its “Nao Rui Jia” product, leveraging its own R&D capabilities and the vast health big data accumulated from Meinian Onehealth’s preventive care services. Guided by clinical needs, the company will jointly establish a “Consortium for Early Screening, Diagnosis, and Treatment of Brain Diseases” with top-tier (Grade 3A) hospitals, release the “Healthy China Initiative and Expert Consensus on Early Screening, Diagnosis, and Treatment of Brain Diseases,” and promote the development of brain disease prevention and control. Furthermore, utilizing Meinian Onehealth’s health examination service network covering 293 cities across China as an entry point, the core technology for intelligent early screening of brain health risks will be extended to a broader population, initiating a real-world study on brain diseases with a sample size of ten thousand participants.

At the conclusion of the summit, Yu Rong, Chairman of Meinian Onehealth Healthcare Holdings Co., Ltd., stated:“‘Traffic portals’ and ‘health data’ have become new forms of medical capital. As a super traffic portal, Meinian Onehealth will fully leverage big health data to build an ecosystem with strong incubation capabilities, empower a cohort of highly correlated upstream and downstream unicorn enterprises, and establish itself as a platform-based company in the broader health industry. While driving the development of high-potential sectors, it remains committed to contributing to the advancement of China’s health industry.”

Meinian Onehealth Group Chairman Yu Rong Delivers Speech

In fact, Meinian Onehealth has already completed its layout in areas including intelligent health risk assessment, smart health management, intelligent gastric health screening, pulmonary health screening, mental health services, diabetic retinopathy screening, and immune cell storage services. Brain health warning and screening is a crucial component in Meinian Onehealth’s effort to perfect its full-lifecycle health management and close-loop health management services.

In the future, Meinian Onehealth and Jingsan Technology will leverage Meinian’s vast accumulation of health data and upgraded algorithmic models to continuously enhance and iterate the “Nao Rui Jia” product, further optimizing its detection accuracy and professional specialization, with the aim of establishing a demonstrative and leading role in the field of preventive medicine for brain health in China.

With the launch of the “Nao Rui Jia” product, it is evident that Meinian Onehealth is expanding its business scope from traditional disease prevention and screening to a broader range of novel major disease prevention. In the future, Meinian Onehealth will adhere to the principle of “prevention first,” continuously leveraging “data + technology” as its core driver. By relying on information platforms, big data, and artificial intelligence technologies, the company aims to empower quality improvement across the entire process—pre-examination, during examination, and post-examination—thereby further increasing the detection rate of significant abnormal results. Additionally, Meinian Onehealth will continually introduce specialized, refined, distinctive, and innovative product series to better meet the public’s demand for high-quality healthcare, ultimately building a comprehensive, full-lifecycle digital health management platform.